Primary effusion lymphoma (PEL) revisited: a hematologist's perspective.
Desai
Samir
S
Providence VA Medical Center, Providence, RI 02908, USA.
Freeman
Nancy J
NJ
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006405:Hematology; D019288:Herpesvirus 8, Human / Q000472:pathogenicity; D006801:Humans; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology* / Q000628:therapy; D008297:Male; D016066:Pleural Effusion, Malignant / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology* / Q000628:therapy; D018700:Pleurodesis; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone